

## CD26/DPPIV and response to hepatitis B vaccination

Marília Dourado<sup>a,\*</sup>, Vera Alves<sup>b</sup>, Luis Mesquita<sup>a</sup>, Isabel Ramos<sup>c</sup>, Anabela Mota Pinto<sup>a</sup>,  
Manuel Santos Rosa<sup>b</sup>

<sup>a</sup> *Institute of General Pathology, Faculty of Medicine, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal*

<sup>b</sup> *Immunology Institute, Faculty of Medicine, University of Coimbra, Rua Larga, 3004-504 Coimbra, Portugal*

<sup>c</sup> *Infectious Disease Service, University Hospital of Coimbra, Av. Dr. Bissaya Barreto, 3000 Coimbra, Portugal*

Accepted 2 June 2004

### Abstract

The prevention of hepatitis B is important, since it is responsible for significant morbidity and mortality around the world. Unfortunately, hepatitis B vaccine does not always induce protective immunity. The lack of immune response to vaccine (non-responders) can depend on individual characteristics.

The objective of this study was to correlate the CD26/DPPIV cellular expression and DPPIV serum activity with HBV vaccine response and its possible role as an indicator of immune competence acquisition. We also determined the cellular expression of CD3, CD19, CD56 and CD25 in peripheral blood T lymphocytes.

Blood samples were obtained from 28 healthy human volunteers who were enrolled with a vaccination program. There were “responders” (RM = 13) and “non-responders” (NRM = 15), after vaccination. The lymphocyte populations were identified by flow cytometry. DPPIV serum activity was measured fluorimetrically.

CD26 expression in responders ( $55.9 \pm 7.7\%$ ) versus in non-responders ( $51.9 \pm 7.0\%$ ) did not show a significant difference. The DPPIV serum activity in responders compared to in non-responder subgroup ( $59.9 \pm 8.4/50.3 \pm 10.6$  U/L) showed, however, a significant difference ( $P < 0.05$ ). The expression of CD3, CD19 and CD56 on peripheral lymphocytes was similar between responders and non-responders. The expression of CD3CD26 ( $52.2 \pm 8.6\%$ ) and CD3CD25 ( $10.9 \pm 3.8\%$ ) in responders versus the expression of CD3CD26 ( $48.0 \pm 5.7\%$ ) and CD3CD25 ( $8 \pm 4.6\%$ ) in non-responders did not show statistically significant difference.

CD25 referred as a marker of T lymphocyte activation was increased in responders ( $15.8 \pm 4.5\%$ ) versus in non-responders ( $10.1 \pm 4.8\%$ ), showing a significant difference ( $P = 0.003$ ). It was, however, impossible to demonstrate an increase in CD3CD25 and CD3CD26 in the responder subgroup. This suggests that different lymphocyte subsets other than T cells are implicated in the response to hepatitis B vaccination.  
© 2004 Published by Elsevier Ireland Ltd.

**Keywords:** Hepatitis B; Vaccination response; Dipeptidyl peptidase IV (DPPIV); CD26; Immune response

### 1. Introduction

Hepatitis B is one of the most important infectious diseases around the world. Its importance is due to the enormous number of infected persons, about two billion. It is also due to its subsequent complications such as fulminant and fatal acute hepatitis, chronic liver disease with cirrhosis and even hepatocellular carcinoma. The chronic carriers constitute the main human reservoir of hepatitis B [1,2]. Groups with high rates of hepatitis B virus (HBV) infection include also healthcare workers daily exposed to blood and other

body fluids. In these particularly exposed groups, vaccination programs are indicated, since the hospital-wide hepatitis B immunisation programme helps to raise the immune status of the staff, and to reduce the costs of prophylactic usage of hepatitis B immunoglobulin.

The recombinant hepatitis B virus vaccine has been used for more than a decade. It consists in non-glycosylated HbsAg particles, but it is otherwise indistinguishable from natural HbsAg. It is comparable, in immunogenicity, protective efficacy and safety to the first generation plasma-derived vaccine [1,3].

Unfortunately, 2–10% of healthy and immunocompetent adults do not respond to vaccination with the production of protective levels of anti-HBS antibody. This fact could be related to a diversity of factors such as:

\* Corresponding author. Tel.: +351 239 822547;

fax: +351 239 822547.

E-mail address: mdourado@fmed.uc.pt (M. Dourado).

sex, age, genetic factors, and some environmental factors [4].

Nevertheless, as hepatitis B is a preventable disease by immunization, the most efficient way to prevent it, is a vaccination program. It is agreed that a universal hepatitis B vaccination should be encouraged in order to reduce the morbidity and the mortality attributable to liver disease and its complications [5,6].

Traditionally HBV vaccination response markers have been the anti-Hbs antibodies serum titers (>100 U/L, responders; <10 U/L, non-responders). The knowledge of the mechanisms by which the immune response can be induced is important, and so is the knowledge of new peripheral blood cell markers, which should give an overview of the immune system pathways.

Dipeptidyl peptidase IV (DPPIV), a membrane bound exopeptidase, has been identified as the surface antigen CD26. Like several other surface enzymes, CD26/DPPIV is expressed on a variety of tissues and cell types, including the T cells, in particular in memory T lymphocytes, as well as on the endothelial and epithelial cells [7].

CD26/DPPIV is a multifunctional molecule that interferes with many immune functions, both in vitro and in vivo. In addition to its membrane-associated form, CD26/DPPIV is also present as a soluble exopeptidase in various body fluids, such as plasma, serum and urine [8–21].

DPPIV has an unique aminopeptidase activity. It cleaves dipeptides from the NH<sub>2</sub>-terminus of proteins, having a proline, a hydroxyproline or an alanine residue at the penultimate position, with the highest efficiency observed with proline residues [13,19,22–25].

Independently of its peptidase activity, CD26/DPPIV is associated to other molecules on the cell surface. For instance, on T lymphocytes, it is associated with CD45, a cell surface expressed phosphotyrosine phosphatase, which is involved in signal transduction. It has been shown to be the main receptor of adenosine deaminase of the T-cell surface, thus protecting the cell from adenosine mediated inhibition of proliferation. In addition, it has also been proposed that CD26 is involved in the pathophysiology of the acquired immune deficiency syndrome (AIDS). It is clear that CD26/DPPIV is involved in multiple functional activities related with immune response. [10–12,14,15,22,26–37].

Both features of CD26/DPPIV, as a membrane antigen and as a peptidase, contribute to the co-stimulation of CD26 in T-cell activation events. The role of CD26/DPPIV in these events is, however, unclear [10,14,38–40].

In view of the established relevance of CD26/DPPIV as a T-cell activation marker our aim was to clarify whether its expression on T cells would change after hepatitis B vaccination and, according to the vaccination response, what differences are observed [8]. Therefore, we studied the expression of CD26 in the peripheral blood T lymphocytes and serum DPPIV activity. The main lymphocyte populations (CD3, CD19 and CD56), were also studied for comparison to see the expression rate of CD26 in T lymphocytes

(CD3) and also of CD25, a known marker of T lymphocyte activation.

## 2. Materials and methods

### 2.1. Subjects and blood sampling

Healthy volunteer healthcare workers ( $M = 28$ ) at the University Hospital of Coimbra (HUC) who were enrolled in an anti-HBV vaccination program, proposed by the medical service of the hospital, participated in this study.

After the vaccination program, individuals were grouped as: “responders” (R), anti-Hbs >100 UI/L ( $n = 13$ ) and “non-responders” (NR), anti-Hbs <10 UI/L ( $n = 15$ ).

Peripheral blood samples (10 mL) were obtained by venous puncture. The samples were divided in two aliquots: 4 mL were collected with EDTA to perform flow cytometry analysis; 6 mL was collected without anticoagulant and allowed to clot at room temperature, centrifuged at  $2000 \times g$ , for 15 min, and the serum was removed and stored at  $-30^\circ\text{C}$ , until assayed.

### 2.2. Flow cytometry

We used monoclonal antibodies that were directly conjugated to one of the following fluorochromes: fluorescein isothiocyanate (FICT), phycoerythrin (PE), or phycoerythrin–cyanin 5.1 (PECy5).

Lymphocyte subsets were studied by two and three colour immunofluorescences with conjugated monoclonal antibodies: anti-CD3 from Dako<sup>®</sup> (PECy5); anti-CD19 (Fitc) and anti-CD56 (PE) from Immunotech<sup>®</sup>, anti-CD26 (PE) and anti-CD25 (PE) from Immune Source<sup>®</sup>. Residual red blood cells were lysed with “Lysing Solution<sup>®</sup>” from Becton Dickinson<sup>®</sup>. Cells were resuspended in phosphate-buffered saline (PBS) until analysis.

Flow cytometry was performed using a FacsCalibur<sup>™</sup> from Becton Dickinson, collecting 10,000 events by acquisition. The lymphocyte population was identified by light scattering and fluorescent properties, gated and analysed.

### 2.3. Serum DPPIV activity was measured by a fluorimetric assay previously described by Sharpé et al. [41]

DPPIV was recorded by the cleavage of the fluorogenic substrate Gly-Pro-4-Me-2-NA, Sigma–Aldrich Co. (St. Louis, 63178 Missouri, USA) releasing a highly fluorescent molecule: 4-Me-2-NA. For the substrate solution, 20 mmol/L, substrate was dissolved in 1 mL of DMSO. This solution was stored at  $4^\circ\text{C}$ .

Standard solution, 4-Me-2-NA was acquired from Bachem Feinchemikalien AG, (Budendorf, Switzerland). The stock solution was 50 mmol/L 4-Me-2-NA in DMSO. Before use it was dissolved as required with stopping solution.

Incubation buffer was a 50 mmol/L Tris–HCl solution, pH 8.3, adjusted at room temperature, stored at 4 °C. Stopping solution was a 100 mmol/L citrate solution, pH 4.0, adjusted at room temperature and stored at the refrigerator at 4 °C. The fluorescence was measured with a JASCO FP-777 spectrofluorimeter, with a quartz cell, at 340 nm of excitation and at 425 nm of the emission wavelengths.

Serum DPPIV activity has been expressed in units/litre (U/L). One unit (U) of DPPIV activity was defined as the enzyme activity that produced 1  $\mu$ mol of 4-Me-2-NA in 1 min under the reaction conditions.

#### 2.4. Statistical analysis

Student's *t*-test was used to determine the statistical significance, considering a *P*-value of <0.05 being significant.

### 3. Results

CD26 expression in responders (55.9  $\pm$  7.7%) versus in non-responders to hepatitis B vaccine (51.9  $\pm$  7.0%) did not show a significant difference (Table 1, Fig. 1).

In the two studied subgroups, serum DPPIV activity was higher in R subgroup (59.9  $\pm$  8.4 U/L) when compared to the enzyme activity in NR subgroup (50.3  $\pm$  10.6 U/L) with a statistical significance (*P* < 0.05) (Table 2, Fig. 2).

Table 1

Monoclonal antibody markers—CD3, CD19, CD56, CD25, CD26, CD3CD26 and CD3CD25—in hepatitis B virus vaccinated, “non-responders” and “responders”

|                | Non-responders ( <i>n</i> = 15) | Responders ( <i>n</i> = 13) |
|----------------|---------------------------------|-----------------------------|
| CD3 (%)        | 79.6 $\pm$ 4.8                  | 79.0 $\pm$ 7.7              |
| CD19 (%)       | 9.6 $\pm$ 3.1                   | 10.3 $\pm$ 3.8              |
| CD56 (%)       | 10.7 $\pm$ 3.8                  | 10.7 $\pm$ 4.8              |
| CD25* (%)      | 10.1 $\pm$ 4.8                  | 15.8 $\pm$ 4.5              |
| CD26 (%)       | 51.9 $\pm$ 7.0                  | 55.9 $\pm$ 7.7              |
| CD3CD25 (%)    | 7.9 $\pm$ 4.6                   | 10.9 $\pm$ 3.8              |
| CD3CD26 (%)    | 49.0 $\pm$ 6.8                  | 52.2 $\pm$ 8.6              |
| CD3negCD26 (%) | 2.8 $\pm$ 1.8                   | 3.8 $\pm$ 1.6               |

Results are expressed in percentage of cells. CD26 is mainly expressed by CD3 T lymphocytes, since CD3neg cells only expressed  $\pm$ 2.8% of total CD26.

\* *P* = 0.003.

Table 2

Protease DPPIV activity (U/L) in hepatitis B virus vaccinated group of healthcare workers grouped, according to the vaccination response, in “non-responders” and “responders”

|                                 | DPPIV (U/L)     |
|---------------------------------|-----------------|
| Non-responders ( <i>n</i> = 15) | 50.3 $\pm$ 10.6 |
| Responders ( <i>n</i> = 13)     | 59.8 $\pm$ 8.4  |

The “responders” showed a higher, and statistically significant, DPPIV activity compared with “non-responders” DPPIV activity. Student's *t*-test: \**P* < 0.05.

The CD3, CD19 and CD56 expression in T lymphocytes was similar take in R and NR subgroups. The expression of CD3CD26 (52.2  $\pm$  8.6%) and CD3CD25 (10.9  $\pm$  3.8%) in responders versus (48.0  $\pm$  5.7%) and (8  $\pm$  4.6%), respectively, in non-responders, was not statistically significant.

In responders, the expression of CD25 (15.8  $\pm$  4.5%) demonstrated a higher and significant difference when compared with non-responders (10.1  $\pm$  4.8%) (*P* = 0.003).

### 4. Discussion

The vaccination is the most important way to protect the population against hepatitis B, since all are vulnerable due to its infectivity and its complications such as acute and fulminating hepatitis, cirrhosis and hepatocellular carcinoma [2,42].

Healthcare workers are daily in exposure risk to infected body fluids. That makes adequate hepatitis B immunisation of healthcare workers a priority.

The effectiveness of hepatitis B vaccines is well known. As previously mentioned traditionally serum titers of antibodies are classical markers of protective immunity to HBV infection. Unfortunately, a number of apparently healthy and immunocompetent adults (2–10%) are unable to achieve protective concentration of antibodies (>100 U/L) after vaccination. This suggests a defect in either B- or T-cell functions in non-responder individuals [43,44]. Nevertheless, antibody concentration only demonstrates a small part of the complexity of immune response, without any information about immune efficacy. The lack of response to hepatitis B vaccination remains a problem for those individuals who are directly in risk of hepatitis B infection.

When activated, T- and B-lymphocytes express a number of surface molecules that are absent or present in low concentrations in resting lymphocytes. Among these molecules are enzymes such as proteases like DPPIV, E.C.3.4.14.5 also known as CD26. It has become a subject of specific interest since it appears to have additional functions in T-cell activation as a co-stimulator molecule [14,39,45,46]. The presence of DPPIV in serum varies widely between individuals, and it is increased upon cell activation. Previous studies have shown roles for CD26 in T-cell activation. It is speculated that CD26/DPPIV is potentially important in the achievement of immunocompetence [7,47,48].

DPPIV cleaves several cytokines, which could change the characters of the local inflammatory response, affecting the differentiation of responding lymphocytes into helper, cytotoxic and regulatory cell populations [7]. The mechanism through which DPPIV influence T-cell functions has not, however, been completely established [49].

The increase of CD26 expression in T-lymphocyte and macrophage membranes has been linked to cell activation and development of immunological memory [49–51].




Fig. 1. CD26 expression in peripheral blood T lymphocytes, on responders and non-responders. Data in percentage of cells that expressed CD26 surface antigen.

The molecular mechanisms by which CD26 mediates the T-cell stimulation/activation mechanisms appear to be associated to the T-cell receptor (TCR), according to some authors, but the role of this molecule in the regulation of the immune response is only partly established [45,52].

According to other authors, the level of DPPiV activity is not directly related to the intensity of CD26 expression on the T cells [4,46]. Findings of others have led to the proposal that DPPiV/CD26 may be involved in the switching of the innate and acquired immune response [53].

Our present results showed that DPPiV serum activity was significantly increased in the responders after vaccination. In our opinion, these DPPiV increased serum levels may be related to successful activation of immune system and to the acquisition of immune efficiency. Other workers have published a significant decrease in T-cell proliferation, cytokine levels and antibody production under the influence of DPPiV specific inhibitors [14,54].

The expression of CD26 on the peripheral blood T lymphocytes did not show a significant difference between the R and NR subgroups. The CD26 expression on CD3 lymphocytes, could be related to cells other than T lymphocytes, and the present result may be due to insufficient sample size.

The increased significant DPPiV activity and the referred modification of CD26 expression, in the responder subgroup, might reflect an improvement in the individual immune status after vaccination. This is emphasised by the significant increase of CD25 (a classical marker of T lymphocyte activation) expression on R subgroup. This could render a greater capacity to react against infection.

It remains to be proved that antibody concentration is the best immunity marker of immune competence after hepatitis B vaccination as the immunological memory, among many others, are involved in the protection of vaccinated organisms.

Further studies, involving larger sample sizes and additional complementary markers of immune protection will probably answer some of the remaining questions that continue to challenge our knowledge of CD26/DPPiV intervention in HBV immunisation.




Fig. 2. Representation of DPPiV activity (U/L) in responders and non-responders hepatitis B virus, after vaccination.

## References

- [1] J.L. Dienstag, J.R. Wands, K.J. Isselbacher, Acute hepatitis, in: Harrison's—Principles of Internal Medicine, 12<sup>a</sup> ed., McGraw-Hill Inc., New York, 1991, pp. 1322–1337.
- [2] A.S. Lok, Hepatitis B infection: pathogenesis and management, *J. Hepatol.* 32 (Suppl. 1) (2000) 89–97.
- [3] M. Adler, N. Bourgeois, Therapeutic approach to chronic hepatitis B and C in the dawn of the third millenium, *Rev. Med. Brux.* 22 (3) (2001) 141–151.
- [4] H. Van Loveren, J.G. van Amsterdam, R.J. Vandebriel, T.G. Kimman, H.C. Rumke, P.S. Steerenberg, J.G. Vos, Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors, *Environ. Health Perspect.* 109 (8) (2001) 7557–7564.
- [5] N. Saadallah, N. Jaoua, A. Ben Hamida, T. Najjar, B. Zouari, Vaccination against viral hepatitis B for public health personnel: the case

- of the National Fund of Social Security, Tunis. *Med.* 79 (12) (2001) 676–680.
- [6] G.A. Kardar, M. Jeddi-Tehrani, F. Shokri, Diminished Th1 and Th2 cytokine production in healthy adults nonresponders to recombinant hepatitis B vaccine, *Scand. J. Immunol.* 55 (3) (2002) 311–314.
- [7] P. Ruiz, L. Hao, K. Zucker, N. Zacharievich, A.L. Viciania, M. Shenkin, J. Miller, Dipeptidyl peptidase IV (CD26) activity in human alloreactive T cell subset varies with the stage of differentiation and activation status, *Transplant Immunol.* 5 (1997) 152–161.
- [8] G. Vanham, L. Kestens, I. De Meester, J. Vingerhoets, G. Penne, G. Vanhoof, S. Sharpé, H. Heyligen, E. Bosmans, J.L. Ceuppens, P. Gigase, Decreased expression of the memory marker CD26 on both CD4 and CD8 T lymphocytes of HIV-infected subjects, *J. Acquir. Immune Defic. Syndr.* 6 (7) (1993) 749–757.
- [9] J. van Damme, S. Struyf, A. Wuyts, E. van Coillie, P. Menten, D. Schols, S. Sozzani, I. De Meester, P. Proost, The role of CD26/DPPIV in chemokine processing, *Chem. Immunol.* 72 (1999) 42–56.
- [10] C. Nguyen, J. Blanco, J.-P. Mazaleyrat, B. Krust, C. Callebaut, E. Jacotot, A.G. Hovanessian, M. Wakselman, Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26a, *J. Med. Chem.* 41 (12) (1998) 2100–2110.
- [11] M.-L. Gougeon, H. Lecoeur, C. Callebaut, E. Jacotot, A. Dulioust, R. Roué, L. Montgnier, A.G. Hovanessian, Selective loss of the CD4+/CD26+ T-cell subset during HIV infection, *Res. Immunol.* 147 (1996) 5–8.
- [12] O.J. Cordero, F.J. Salgado, J.E. Viñuela, M. Nogueira, Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on activated lymphocytes, *Immunobiology* 197 (5) (1997) 522–533.
- [13] A.-M. Lambeir, M. Borloo, I. De Meester, A. Belyaev, K. Augustyns, D. Hendriks, S. Sharpé, A. Haemers, Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV, *Biochim. Biophys. Acta* 1290 (1996) 76–82.
- [14] I. De Meester, S. Korom, J. van Damme, S. Scharpé, CD26, let it cut or cut it down, *Immunol. Today* 20 (8) (1999) 367–375.
- [15] S. Iwata, N. Yamaguchi, Y. Munakata, H. Ikushima, J.F. Lee, O. Hosono, S.F. Schlossman, C. Morimoto, CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T-cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response, *Int. Immunol.* 11 (3) (1999) 417–426.
- [16] C.A. Abbott, E. Baker, G.R. Sutherland, G.W. McCaughan, Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene, *Immunogenetics* 40 (1994) 331–338.
- [17] R.C. Johnson, D. Zhu, H.G. Augustin-Voss, B.U. Pauli, Lung endothelial dipeptidyl peptidase IV is an adhesion molecule for lung—metastatic rat breast and prostate carcinoma cells, *J. Cell Biol.* 121 (6) (1993) 1423–1432.
- [18] S. Korom, I. De Meester, T.H.W. Stadlbauer, A. Chandraker, M. Schaub, M.H. Sayegh, A. Belyaev, A. Haemers, S. Sharpé, J.W. Kupiec-Weglinski, W. Jerzy, Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients, *Transplant* 63 (10) (1997) 1495–1500.
- [19] M. Borloo, I. De Meester, Dipeptidyl peptidase IV: development, design, synthesis, and biological evaluation of inhibitors, *Werk-K-Acad-Genceskd-Belg* 56 (1) (1994) 57–88.
- [20] A. Sedo, E. Krepela, E. Kasafirek, A kinetic fluorometric assay of dipeptidyl peptidase IV in viable human blood mononuclear cells, *Biochemistry* 71 (1989) 757–761.
- [21] M. Maes, S. Scharpé, I. De Meester, P. Goossens, A. Wauters, H. Neels, R. Verkerk, F. De Meyer, P. D'Hondt, D. Peeters, C. Schotte, P. Cosyns, Components of biological variation in prolyl endopeptidase and dipeptidyl-peptidase IV activity in plasma of healthy subjects, *Clin. Chem.* 40 (9) (1994) 1686–1691.
- [22] R.E. Smith, J.W. Talhouk, E.E. Brown, S.E. Edgar, The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding, *AIDS Res. Human Retroviruses* 14 (10) (1998) 851–868.
- [23] I. De Meester, A. Belyaev, A.-M. Lambeir, G.R.Y. De Meyer, N.V. Osselaer, A. Haemers, S. Sharpé, In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (prodipine), *Biochem. Pharmacol.* 54 (1997) 173–179.
- [24] G. Bou-Gharios, J. Osman, A. Athaeton, P. Monaghan, R. Vancheeswaran, C. Black, I. Olsen, Expression of ectopeptidases in scleroderma, *Ann. Reum. Dis.* 54 (1995) 111–116.
- [25] I. De Meester, S. Scharpé, G. Vanham, E. Bosmans, H. Heyligen, G. Vanhoof, G. Corte, Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster, *Immunobiology* 188 (1993) 145–158.
- [26] S.H. Low, B.L. Tang, S.H. Wong, W. Hong, Selective inhibition of protein targeting to the apical domain of MDCK cells by brefeldin A, *J. Cell Biol.* 118 (1) (1992) 51–62.
- [27] J. Kameoka, T. Tanaka, Y. Nojima, S.F. Schlossman, C. Morimoto, Direct association of adenosine deaminase with a T-cell activation antigen, CD26, *Science* 261 (1993) 466–469.
- [28] C.A. Abbott, G.W. McCaughan, M.T. Levy, W.B. Church, M.D. Gorrrell, Binding to human dipeptidyl peptidase IV by adenosine deaminase and antibodies that inhibit ligand binding involves overlapping, discontinuous sites on a predicted beta propeller domain, *Eur. J. Biochem.* 266 (3) (1999) 798–810.
- [29] T. Tanaka, J. Kameoka, A. Yaron, S.F. Schlossman, C. Morimoto, The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity, *Proc. Natl. Acad. Sci. U.S.A.* 90 (1993) 4586–4590.
- [30] Y. Torimoto, N.H. Dang, E. Vivier, T. Tanaka, S.F. Schlossman, C. Morimoto, Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T-lymphocytes, *J. Immunol.* 147 (8) (1991) 2514–2517.
- [31] J.S. Duke-Cohan, C. Morimoto, J.A. Rocker, S.F. Schlossman, A novel form of dipeptidyl peptidase IV found in human serum— isolation, characterization, and comparison with T-lymphocyte membrane dipeptidyl peptidase IV (CD26), *J. Biol. Chem.* 270 (23) (1995) 14107–14114.
- [32] M.A. Shipp, A.T. Look, Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! *Blood* 82 (4) (1993) 1052–1070.
- [33] A. Bertotto, R. Gerli, F. Spinuzzi, C. Muscat, G.M. Fabietti, S. Crupi, J. Castellucci, F.M. De Benedictis, G. De Giorgi, R. Britta, C. Vagliasindi, N. Forenza, R. Vaccaro, CD26 surface antigen expression on peripheral blood T lymphocytes from children with Down's syndrome (trisomy 21), *Scand. J. Immunol.* 39 (1994) 633–636.
- [34] T. Ohtsuki, O. Hosono, H. Kobayashi, Y. Munakata, A. Souta, T. Shioda, C. Morimoto, Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor 1a by CD26/dipeptidyl peptidase IV, *FEBS Lett.* 431 (2) (1998) 236–240.
- [35] C. Callebaut, A.G. Hovanessian, CD26 and HIV infection, *Res. Virol.* 147 (1996) 67–69.
- [36] M.J. Feito, M. Bragardo, D. Buonfiglio, S. Bonisconi, F. Bottarel, F. Malvasi, U. Dianzani, gp120s derived from four syncytium-inducing HIV-1 strains induce different patterns of CD4 association with lymphocyte surface molecules, *Int. Immunol.* 9 (8) (1997) 1141–1147.
- [37] O. Hosono, T. Homma, H. Kobayashi, Y. Munakata, Y. Nojima, A. Iwamoto, C. Morimoto, Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals, *Clin. Immunol.* 91 (3) (1999) 283–295.
- [38] D. Reinhold, U. Bank, F. Bühling, K. Neubert, T. Mattern, A.J. Ulmer, H.D. Flad, S. Ansorge, Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed

- mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production, *Immunobiology* 188 (1993) 403–414.
- [39] B. Fleischer, CD26: a surface protease involved in T-cell activation, *Immunol. Today* 15 (4) (1994) 180–184.
- [40] F. Bühling, D. Kunz, D. Reinhold, A.J. Ulmer, M. Ernest, H.-D. Flad, S. Ansoerge, Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells, *Nat. Immunol.* 13 (1994) 270–279.
- [41] S. Scharpé, I. De Meester, G. Vanhoof, D. Hendriks, M. van Sande, K. van Camp, A. Yaron, Assay of dipeptidyl peptidase IV in serum by fluorometry of 4-methoxy-2-naphthylamine, *Clin. Chem.* 34 (11) (1988) 2299–2301.
- [42] G. Webster, A. Bertoletti, Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection, *Mol. Immunol.* 38 (6) (2001) 467–473.
- [43] M.A. Shokrgozar, F. Shokri, Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen, *Immunology* 104 (1) (2001) 75–79.
- [44] T. Suzuki, K. Yamauchi, T. Kuawata, N. Hayashi, Characterization of hepatitis B virus surface-specific CD4+ cells in hepatitis B vaccine non-responders, *J. Gastroenterol. Hepatol.* 16 (8) (2001) 898–903.
- [45] O.J. Cordero, F.J. Salgado, J.E. Viñuela, M. Nogueira, Interleukin-12-dependent activation of human lymphocyte subsets, *Immunol. Lett.* 61 (1) (1998) 7–13.
- [46] F. Bühling, U. Junker, D. Reinhold, K. Neubert, L. Jager, S. Ansoerge, Functional role of CD26 on human B lymphocytes, *Immunol. Lett.* 45 (1995) 47–51.
- [47] N.H. Dang, Y. Torimoto, K. Deusch, S.F. Schlossman, C. Morimoto, Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways, *J. Immunol.* 144 (11) (1990) 4092–4100.
- [48] J. Bednarczyk, S.M. Carrol, C. Marin, B. McIntyre, Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation, *J. Cell Biochem.* 46 (1991) 206–218.
- [49] T. Oravec, M. Pall, G. Roderiquez, M.D. Gorrell, M. Ditto, N.Y. Nguyen, R. Boykins, E. Unsworth, M.A. Norcross, Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage, *J. Exp. Med.* 186 (11) (1997) 1865–1872.
- [50] M. Willheim, C. Ebner, K. Baier, W. Kern, K. Schratlbauer, R. Thien, D. Kraft, H. Breiteneder, W. Reinisch, O. Scheiner, Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with TH1 subsets, *J. Allergy Clin. Immunol.* 100 (1997) 348–355.
- [51] D. Reinhold, R.W. Vetter, K. Munich, F. Bühling, U. Lendeckel, I. Born, J. Faust, K. Neubert, H. Gollnick, S. Ansoerge, Dipeptidyl peptidase IV (DPPIV, CD26) is involved in regulation of DNA synthesis in human keratinocytes, *FEBS Lett.* 428 (1–2) (1998) 100–104.
- [52] T. Kähne, H. Kröning, U. Thiel, A.J. Ulmer, H.-D. Flad, S. Ansoerge, Alterations in structure and cellular localization of molecular forms of DP IV/CD26 during T cell activation, *Cell Immunol.* 170 (1996) 63–70.
- [53] S. Iwata, C. Morimoto, CD26/dipeptidyl peptidase IV in context: the different roles of a multifunctional ectoenzyme in malignant transformation, *J. Exp. Med.* 190 (3) (1999) 301–305.
- [54] T. Kubota, G.R. Flentke, W.W. Bachovchin, B.D. Stollar, Involvement of dipeptidyl peptidase IV in an in vivo immune response, *Clin. Exp. Immunol.* 89 (1992) 192–197.